SCHEMBL1997952

SCHEMBL1997952

CC(=O)NCCOc1ccc2c(ccn2S(=O)(=O)c2ccccc2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 10/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
POLB P06746 1/20 0.61
HDAC1 Q13547 10/20 0.56
HDAC6 Q9UBN7 6/20 0.56
MTNR1A P48039 1/20 0.51
MTNR1B P49286 1/20 0.51
HDAC3 O15379 4/20 0.50
HDAC2 Q92769 4/20 0.50
HDAC4 P56524 2/20 0.50
HDAC7 Q8WUI4 2/20 0.50
HDAC10 Q969S8 2/20 0.50
HDAC11 Q96DB2 2/20 0.50
HDAC8 Q9BY41 2/20 0.50
HDAC9 Q9UKV0 2/20 0.50
HDAC5 Q9UQL6 2/20 0.50
NCOR2 Q9Y618 2/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
BCHE P06276 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1993693 0.89 HTR6 (0.57) HTR6L3MBTL1POLBHDAC1HDAC6
SCHEMBL4409876 0.85 HTR6 (0.53) HTR6L3MBTL1POLBHDAC1HDAC6
SCHEMBL1998285 0.82 HTR6 (0.51) HTR6BCHE
SCHEMBL2000822 0.82 HTR6 (0.52) HTR6L3MBTL1POLBMTNR1AMTNR1B
SCHEMBL1996167 0.81 HTR6 (0.67) HTR6L3MBTL1POLBHDAC1HDAC6
SCHEMBL2002274 0.81 HTR6 (0.48) HTR6L3MBTL1MTNR1AMTNR1BMEN1
SCHEMBL25455094 0.80 HTR6 (0.66) HTR6L3MBTL1POLBHDAC1HDAC6
SCHEMBL707042 0.77 HDAC1 (0.74) HTR6L3MBTL1POLBHDAC1HDAC6
SCHEMBL430473 0.76 HTR6 (1.00) HTR6L3MBTL1POLBHDAC1HDAC6
SCHEMBL7017328 0.76 HTR6 (0.63) HTR6MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960374-B2 e.g. 2,5-methylene-9-(phenylsulfonyl)-1,2,3,4,5,9-hexahydro[1,5]oxazocino[3,2-e]indole; serotonin receptors antagonist or partial agonist; metabolic diseases, e.g. obesity, insulin resisitance, type 2 diabetes, eating disorders; antidepressant, anxiolytic agent; cosmetics PROXIMAGEN LIMITED (GB) 2011-06-14 US disclosed
EP-2091953-A1 8-SULFONYL-L, 3, 4, 8-TETRAHYDR0-2H- [1, 4]OXAZEPINO [6, 7-E]INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 RECEPTOR LIGANDS BIOVITRUM AB (publ) (SE) 2009-08-26 EP disclosed
US-20080176829-A1 Compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2008-07-24 US disclosed
WO-2008054288-A1 8-SULFONYL-L, 3, 4, 8-TETRAHYDR0-2H- [1, 4] OXAZEPINO [6, 7-E] INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 RECEPTOR LIGANDS BIOVITRUM AB (PUBL) (SE) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176829-A1 Compounds HTR6, HTR1B, HTR1A HTR6 1/4885L3MBTL1 4817/4885POLB 4076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.